KDMN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases...

Stats
Today's Volume	10.42M
Average Volume	10.03M
Market Cap	0.00
EPS	$-0.200 ( 2021-11-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.32
ATR14	$0.213 (2.24%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-09	Waksal Harlan	Sell	177 945	Common Stock
2021-11-09	Waksal Harlan	Buy	655 000	Stock Appreciation Right
2021-11-09	Waksal Harlan	Buy	982 500	Performance Stock Option(right to buy)
2021-11-09	Waksal Harlan	Buy	1 350 000	Stock Option (right to buy)
2021-11-09	Waksal Harlan	Buy	2 000 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 93 transactions
Buy: 16 325 233 \| Sell: 4 159 124

Volume Correlation

Long: 0.23 (neutral)

Short: 0.86 (strong)

Signal:(72.9) Same movement expected

Kadmon Holdings Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kadmon Holdings Inc Correlation - Currency/Commodity

0.41
( neutral )

0.05
( neutral )

-0.66
( moderate negative )

-0.67
( moderate negative )

0.54
( weak )

0.03
( neutral )

Kadmon Holdings Inc Financials

Annual	2020
Revenue:	$8.29M
Gross Profit:	$6.29M (75.86 %)
EPS:	$-0.670

Q3	2021
Revenue:	$14.71M
Gross Profit:	$14.06M (95.63 %)
EPS:	$-0.200

Q2	2021
Revenue:	$197 000
Gross Profit:	$186 000 (94.42 %)
EPS:	$-0.180

Q1	2021
Revenue:	$563 000
Gross Profit:	$467 000 (82.95 %)
EPS:	$-0.170

Financial Reports:

No articles found.

Kadmon Holdings Inc

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.